Pathogenica and Life Technologies Japan Release Assay to Detect Hospital Acquired Infections
Pathogenica and Life Technologies Japan partner to deliver unique Hospital Acquired Infection solution using DNA sequencing analysis on the ION Torrent (TM) Platform,
May 3, 2012 - PRLog -- NAGASAKI, JAPAN AND BOSTON, MASSACHUSETTS – Pathogenica, a pioneer in pathogen sequencing analysis, and Life Technologies Japan, today announced an agreement to launch and distribute Pathogenica’
The complete Hospital Acquired Infection (HAI) solution includes Pathogenica’
Each Pathogenica kit provides reagents for identification of the following pathogens and drug resistance markers per sample, including: Acinetobacter baumannii, Clostridium difficile, Escherichia coli, Enterococcus faecalis, Enterococcus faecium, Enterobacter aerogenes, Enterobacter cloacae, Klebsiella pneumonia, Proteus mirabilis, Pseudomonas aeruginosa, Coagulase negative staph (epidermis, saprophyticus)
“Making hospital care safer is a global priority,” explains Yemi Adesokan, co-founder and CEO of Pathogenica. “Our partnership with Life Technologies provides access to many hospitals in Japan where together we can help to begin controlling the spread of infection very quickly.”
The Ion Personal Genome Machine (PGM™) is marked for Research Use Only; not for diagnostic use.
Pathogenica combines the power of Cloud-based DNA sequencing analysis and next-generation DNA sequencing to revolutionize pathogen identification and enable real-time bio-surveillance. Its DxSeq™ platform offers new applications in health services through rapid multiplex identification of pathogens and drug resistance genes; providing personalized diagnosis for infectious diseases that allows for more effective diagnosis and treatment of patients. Pathogenica’
About Life Technologies
Life Technologies Corporation is a global biotechnology company with customers in more than 160 countries using its innovative solutions to solve some of today’s most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum with more than 50,000 products for translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables represent some of the most cited brands in scientific research including: Ion Torrent™, Applied Biosystems®, Invitrogen™, GIBCO®, Ambion®, Molecular Probes®, Novex®, and TaqMan®. Life Technologies employs approximately 10,400 people and upholds its ongoing commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of $3.7 billion in 2011. Visit us at our website: http://www.lifetechnologies.com.
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’